Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts

De-Liang Zhang, Thomas Senecal, Manik C. Ghosh, Hayden Ollivierre-Wilson, Tiffany Tu, Tracey A. Rouault

Molecular Medicine Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892, USA

Correspondence: Tracey A. Rouault, Molecular Medicine Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892, USA email: rouault@mail.nih.gov Tel: 301-496-7060 Fax: 301-402-0078

Running title: Hepcidin regulates iron status of erythroblasts

Scientific category: Red Cells, Iron and Erythropoiesis
Abstract

The iron regulatory hormone, hepcidin, regulates systemic iron homeostasis by interacting with the iron export protein ferroportin (FPN1) to adjust iron absorption in enterocytes, iron recycling through reticuloendothelial macrophages, and iron release from storage in hepatocytes. We previously demonstrated that FPN1 was highly expressed in erythroblasts, a cell type that consumes most of the serum iron for use in hemoglobin synthesis. Herein, we have demonstrated that FPN1 localizes to the plasma membrane of erythroblasts, and hepcidin treatment leads to decreased expression of FPN1 and a subsequent increase in intracellular iron concentrations in both erythroblast cell lines and primary erythroblasts. Moreover, injection of exogenous hepcidin decreased FPN1 expression in bone marrow erythroblasts in vivo, whereas iron-depletion and associated hepcidin reduction led to increased FPN1 expression in erythroblasts. Taken together, hepcidin decreased FPN1 expression and increased intracellular iron availability of erythroblasts.

We hypothesize that FPN1 expression in erythroblasts allows fine-tuning of systemic iron utilisation to ensure that erythropoiesis is partially suppressed when non-erythropoietic tissues risk developing iron deficiency. Our results may explain why iron deficiency anemia is the most pronounced early manifestation of mammalian iron deficiency.
Introduction

FPN1 is the sole iron export protein that has been identified thus far in mammals.\textsuperscript{1} It is highly expressed on the basolateral membrane of duodenal enterocytes where it facilitates the export of newly absorbed dietary iron into the systemic circulation, in reticuloendothelial macrophages where it exports iron recycled from senescent red blood cells into blood, and in hepatocytes where it releases iron from storage. The expression of FPN1 is regulated post-translationally by a small peptide hormone, hepcidin, which is secreted mainly by the liver in response to iron overload, inflammation, hypoxia, and erythropoiesis.\textsuperscript{2} In the circulation, hepcidin binds to FPN1 on the plasma membrane of cells in various tissues and induces its internalization, ubiquitination and degradation, which blocks the flux of iron into the blood stream.\textsuperscript{3,4} Iron overload increases hepcidin expression, probably through a pathway that integrates inputs from molecules such as HFE, TIR2, HJV, BMP6, and TMPRSS6 to regulate hepcidin transcription. High serum hepcidin reduces FPN1 expression and blocks iron flux from tissues into the circulation; conversely, iron deficiency decreases hepcidin expression and allows FPN1 to remain available for transport of iron from tissues into the blood stream.\textsuperscript{2,5,7} Thus, through a feedback mechanism, the hepcidin-FPN1 interaction regulates systemic iron homeostasis. Dysregulation of hepcidin or FPN1 expression is involved in the pathogenesis of diseases such as hemochromatosis,\textsuperscript{8-10} anemia of chronic disease\textsuperscript{11,12} and beta-thalassemia,\textsuperscript{13,14} underlining the importance of hepcidin and FPN in the regulation of systemic iron homeostasis.

In addition to the regulation by hepcidin at the protein level, FPN1 expression can also be regulated at the post-transcriptional level by the iron-regulatory protein (IRP)/iron-responsive element (IRE) machinery.\textsuperscript{15-17} The canonical transcript of FPN1 has a IRE in its 5′UTR, and in
iron-deficient conditions, IRPs can bind to the IRE and repress the translation of FPN1. This translational repression reduces expression of the FPN1 protein in iron-deficient cells, enabling cells to retain intracellular iron when iron availability is limited. However, in contrast to expectations based on regulation by the IRP/IRE machinery, FPN1 protein expression was shown to be upregulated in the duodenum of animals maintained on a low-iron diet. Moreover, FPN1 protein expression in enterocytes needs to be upregulated in iron-deficient animals to provide more iron for systemic iron demands. In the process of investigating the underlying mechanism for upregulation of duodenal FPN1 protein during iron starvation, we previously identified a FPN1 transcript (FPN1B) that does not have a IRE in its 5'UTR. FPN1B is generated from a promoter located upstream of the promoter of the FPN1A transcript (FPN1 transcript that contains the IRE), and encodes the identical ferroportin protein. FPN1B is specifically expressed in enterocytes, and is conserved in both humans and mice. The expression of FPN1B in enterocytes likely enables the cells to evade translational suppression by the IRP/IRE system and to express FPN1 protein under conditions of iron starvation at the potential risk of generating intracellular iron deficiency.

Most strikingly, we found that FPN1B was also highly expressed in erythroblasts of mouse bone marrow, and the protein levels of FPN1 in erythroblasts exceeded those of bone marrow macrophages. The promoter of FPN1B in erythroblasts is regulated through putative GATA and EKLF binding sites, and its expression decreases during differentiation of erythroblasts. To explore the physiological function of FPN1 in erythropoiesis, we investigated the function of FPN1 and its regulation by hepcidin in erythroblasts in vitro and in vivo, and we found that hepcidin regulates FPN1 expression and the intracellular iron homeostasis of erythroblasts.
Materials and Methods

Animals

All of the animals used in this study were C57BL/6 mice and were approved by the NIH institutional review board of animal care committee. For dietary manipulations, newly weaned mice were maintained on low-iron diet (2-10 mg/kg chow) or control diet (200 mg/kg chow) for at least 3 months before hepcidin injection. For hepcidin treatment, the mice were peritoneally injected with hepcidin (Bachem Americas, Inc.) 20 μg per mouse in 0.3 ml of phosphate buffered saline (PBS), with a second dose injected 20 hours later. The control group was injected with PBS only. The animals were sacrificed 24 hours after the first dose injection, and Ter119-positive erythroblasts were isolated with Dynabead (Invitrogen) as described previously. In brief, the bone marrow cells from the femurs were incubated with Dynabeads that had been pre-coated with biotinylated anti-mouse Ter119 antibody (R&D systems), and the Dynabead-cell complexes were then isolated, and cells were lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% Na Deoxycholate, 1% Triton X-100) with Protease inhibitor tablet (Roche) for western blot analysis.

Plasmid preparation, cell culture and transfection

The pEGFP-N1-FPN1 plasmid was generously provided by Dr. Ivana De Domenico (University of Utah); there is no IRE element in its 5'UTR and its product is a FPN1-GFP fusion protein. The pIRES2EGFP-FPN1 vector was created by cloning mouse FPN1 into the pIRES2EGFP vector (Clontech) with XhoI and KpnI sites. The pDsRed-Monomer-F vector was from Clontech Laboratories, Inc. Erythroblast cell lines K562 and MEL were cultured as described previously.
The cells were transfected with 2 µg plasmid per 1x10^6 cells with Neon Transfection system (Invitrogen) according to the manufacturer's protocol, and 30 min after transfection, 100 µM of iron-nitrilotriacetate (FeNTA) was added to the medium to counteract the potential intracellular iron starvation induced by FPN1 overexpression.

**Primary erythroblast cell culture**

The erythroblasts from fetal liver were cultured according to previous protocols with minor modifications. Briefly, cells from the fetal liver of E13.5 days embryos were cultured in StemPro-34 serum-free medium (Invitrogen) supplemented with 2 U/ml human recombinant erythropoietin (EPO), 100 ng/ml murine recombinant stem cell factor, 10 µM synthetic glucocorticoid dexamethasone, 40 ng/ml insulin-like growth factor 1, 2 mM L-glutamine, 75 µg/ml human holo-transferrin, 140 mM monothioglycerol, 100 U/ml Penicillin and 100 µg/ml Streptomycin under 37 °C with 5% CO₂. The cells were maintained in a density of 1-4x10^6 cells/ml, the cell medium was changed daily, and differentiated cells were removed by Ficoll purification every 4-5 days. To induce differentiation, proliferating cells were washed twice with DMEM medium, and then were seeded at about 1-2x10^6 cells/ml in StemPro-34 medium supplemented with 10 U/ml EPO, 4x10^-4 U/ml insulin, 1 mg/ml holo-transferrin, 2 mM L-glutamine, 140 mM monothioglycerol, 100 U/ml Penicillin and 100 µg/ml Streptomycin.

**Microscopy analysis**

To study the localization of FPN1 in K562 cells, the cells were co-transfected with 2 µg per 1x10^6 cells of pEGFP-N1-FPN1 and pDsRed-Monomer-F for 24 hours in medium supplemented with
100 µM FeNTA, and were then checked in a Chambered Coverglass under a confocal microscope.

To study the localization of endogenous FPN1 in primary erythroblasts, fetal liver erythroblasts were fixed in 4% paraformaldehyde in PBS, and were then permeabilized with 0.1% Triton X-100 in PBS with 0.1% BSA. After blocking with 5% donkey serum in PBS, the slides were incubated with rabbit anti-mouse FPN1 antibody (1:100) that we described previously and mouse anti-TfR1 antibody (1:200, Zymed) overnight at 4 °C, followed by incubation with FITC-donkey anti-rabbit and CY3-donkey anti-mouse antibodies (Jackson ImmunoResearch) for 1 hour at room temperature. The pictures were taken with a Leica SP5 confocal microscope.

**Fluorescence activated cell sorting (FACS)**

The GFP-positive cells and TfR1 expression levels were analyzed by FACS on BD FACSCalibur, and the results were acquired and analyzed with CellQuest. For analysis of TfR1 expression in K562 cells, the cells were incubated with APC-labeled anti-human TfR1 antibody (BD Pharmingen) for 30 minutes under 4 °C in PBA buffer (1% bovine serum albumin, 0.1% sodium azide in PBS, pH7.4). To verify cell surface TfR1 expression as an indicator of intracellular iron status, K562 cells were treated with 100 µM of FeNTA or the iron chelator DFO for 18 hours, followed by incubation with APC-mouse anti-human TfR1 antibody, and were subsequently analyzed with FACS. To analyze TfR1 expression in cells transfected with vectors, a gate was set up to analyze the GFP-positive cells only.

**Quantitative real time PCR (qRT-PCR)**

qRT-PCR experiments were performed with SYBR Green PCR master mixture (Applied
Biosystems). Total RNA was prepared with TRIzol reagent (Invitrogen), and cDNA was prepared with High Capacity cDNA Reverse Transcription kit (Applied Biosystems) with 2 μg total RNA. The primers for FPN1, FPN1A, FPN1B, hemoglobin alpha adult chain 1 (HBA) and actin were the same as those described previously.18 The primers for hepcidin were as follows: Forward primer: TTGCGATAACATGCAGAAG, Reverse primer: TGCAACAGATACCACTGG. The results were normalized against actin levels.

**Immunoprecipitation of cell surface proteins, western blot and RNA mobility shift assays**

Fetal liver erythroblasts were incubated with or without 1 μg/ml hepcidin for 24 hours, and were then labeled with or without Sulfo-NHS-LC-Biotin (Pierce) according to the manufacturer's protocol. Biotin-labeled cells were then lysed in RIPA buffer, and cell lysates were incubated with Streptavidin Gel (Pierce) overnight at 4 °C. The protein-streptavidin gel complexes were incubated with loading buffer at 65 °C for 5 min before being loaded to gels for western blot analysis.

Tissues were homogenized in liquid nitrogen and lysates were prepared in homogenizing buffer (50 mM Tris-HCl, pH7.0, 150 mM NaCl, 2 mM EDTA, 1 mM AEBSF and complete Protease Inhibitor Cocktail). For cultured cells, the cell pellet was resuspended in homogenizing buffer and treated with a sonifier (Sonic Dismembrator model 100) for 10 pulses 1 second each at setting 2. The lysates were centrifuged at 7500 g for 10 min, supernatants were centrifuged at 100,000 g for 60 min, and pellets were resuspended in 25 mM Tris-HCl, pH7.0 with 5% glycerol and 0.2% NP-40. The protein concentration was measured with BCA protein assay (Pierce). Protein (50 μg for each sample) was separated with 4-20% Tris-glycine SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The dilution is 1:4000 for the mouse anti-tubulin antibody (Sigma)
and 1:5000, for the rabbit anti-GFP antibody. The antibodies for anti-FPN1 (Map23 antibody that we described previously), TfR1, L-ferritin, IRP1 and IRP2 were used as previously described. The membranes were developed using ECL kit (Pierce). The RNA mobility shift assays were performed as described previously.

Iron-55 retention experiments

Primary erythroblasts from fetal liver in one well of a 6-well plate were loaded with 5 μCi (0.2 μg) 55Fe (PerkinElmer) for 2 hours at 37 °C in proliferation medium, and then were washed with DMEM and cultured in proliferating medium in the presence of hepcidin at the indicated concentration for 24 or 48 hours. After being washed twice with DMEM, 55Fe retained inside the cells was measured with a Liquid Scintillation Counter.

Statistics

All data are presented as mean ± standard deviation, and the statistical analyses were done with the student’s t-test.

Results

FPN1 is localized to the plasma membrane of erythroblast cell lines and primary erythroblasts.

To investigate the localization of FPN1 in erythroblasts, we transiently transfected K562 cells with a plasmid that encodes FPN1GFP (Figure 1A) and we found that FPN1GFP colocalized with the plasma membrane marker DsRed-Monomer-F, suggesting that FPN1 localizes to the plasma
membrane of erythroblasts. Transfected FPN1 also localized to the plasma membrane of mouse
erthroblast cell line MEL cells (Supplemental figure 1A). The localization of endogenous FPN1 was
then investigated in fetal liver erythroblasts using a rabbit anti-mouse FPN1 antibody that we described
previously (Figure 1B).18 The majority of FPN1 colocalized with TfR1 on the plasma membrane, but
some fluorescence observed inside the cells may represent newly synthesized FPN1 that is trafficking
through the Golgi/ER network (Figure 1B). To verify the localization of FPN1 in primary erythroblasts,
cell surface proteins were labeled with biotin and were then pulled down with streptavidin gel, after
which FPN1 levels were analyzed by western blot. As shown in Figure 1C, streptavidin gel
immunoprecipitated endogenous FPN1 in the biotin-labeled samples of primary erythroblasts. Hepcidin
treatment markedly decreased FPN1 levels on the cell surface. As a positive control, TfR1 was also
immunoprecipitated from the biotin labeled samples. In samples not treated with biotin, neither FPN1
nor TfR1 were detected, confirming that FPN1 localizes to the plasma membrane of erythroblasts (Fig.
1C).

**Hepcidin regulates FPN1 expression and intracellular iron levels of erythroblast cells.**

To assess intracellular iron status, we used FACS analysis to evaluate surface expression of TfR1 in
K562 cells. Because the TfR1 transcript has five iron-responsive elements in its 3′-UTR that may be
bound and stabilized by IRP proteins under conditions of iron deficiency, its expression is upregulated
by iron deficiency and downregulated by iron repletion. As shown in Figure 2A, TfR1 signal intensity
was increased by treatment with the iron chelator DFO and decreased by FeNTA supplementation,
verifying that TfR1 expression can be used as an indicator of intracellular iron levels in this assay.
Expression of the FPN1GFP fusion protein in K562 cells resulted in increased TfR1 expression
compared to cells expressing GFP only (Figure 2B), which suggested that FPN1 causes intracellular iron deficiency by exporting iron out of K562 cells. Treatment with 1 μg/ml hepcidin for 24 hours significantly decreased numbers of FPN1GFP-positive cells in both K562 and MEL cells, whereas there was no effect on cells transfected with GFP only, which suggested that hepcidin specifically induces FPN1 degradation in erythroblasts (Figure 2 C and D, Supplemental figure 1B and C).

Hepcidin at a concentration of 1 μg/ml induced FPN1 degradation in a time-dependent manner (Figure 2E); FPN1 levels significantly decreased after 4 hours treatment and were almost 50% decreased after 24 hours, whereas there was no effect on GFP levels in cells expressing GFP alone. Hepcidin also induced FPN1 degradation in a dose-dependent manner (Figure 2F). FPN1 expression was significantly decreased by treatment with 50 ng/ml hepcidin for 24 hours, and its expression was decreased further with increased hepcidin concentrations, such that 2 μg/ml hepcidin decreased FPN1 expression by more than 50%. Notably, there were fewer positive cells in cells expressing FPN1GFP than cells expressing GFP only, perhaps because the properties of FPN1GFP (encoding a membrane protein with 12 potential trans-membrane domains) differ from those of GFP (soluble protein). The effects of hepcidin on FPN1-induced iron deficiency were also studied in K562 cells transfected with the pIRES2EGFP-FPN1 vector. This vector contains an internal ribosomal entry site and generates a single mRNA from which both FPN1 and GFP can be independently translated into two distinct proteins. In transfected cells, GFP expression can thus serve as a marker for cells expressing FPN1, and TfR1 expression can be selectively measured in GFP-expressing cells.

Consistent with Figure 2B, expression of FPN1 significantly increased TfR1 expression (Figure 2G), whereas hepcidin treatment decreased TfR1 expression to a level similar to cells transfected with the vector only, suggesting that hepcidin prevents FPN1 from exporting iron in erythroblast cell lines.
The regulation of hepcidin on FPN1 levels and intracellular iron status was also investigated in K562 cells with western blot analyses (Figure 3). Overexpression of the FPN1GFP fusion protein in K562 for 24 hours increased IRP2 and TfR1 protein expression, whereas treatment with 1 µg/ml hepcidin decreased FPN1 protein levels (confirmed by both anti-GFP and anti-FPN1 antibodies) and restored IRP2 and TfR1 protein levels to levels comparable to those in cells expressing GFP only (Figure 3A). Because IRP1 is a bifunctional enzyme whose activity converts between iron-regulatory protein and cytosolic aconitase in response to changes in intracellular iron concentrations, its protein levels did not change, as expected. Hepcidin induced the degradation of the FPN1GFP fusion protein in a time-dependent manner, and IRP2 and TfR1 protein levels decreased markedly at the 12 and 24 hour time points (Figure 3B). Hepcidin also induced the degradation of FPN1 expression in a dose-dependent manner; treatment with 50 ng/ml hepcidin for 24 hours significantly decreased FPN1 expression, and FPN1 protein decreased further with higher hepcidin levels (up to 2 µg/ml), with IRP2 and TfR1 protein levels decreasing concomitantly (Figure 3C). Consistent with Figure 2, these results implied that FPN1 exported intracellular iron in erythroblast cell lines, whereas hepcidin treatment prevented FPN1 from depleting intracellular iron and restored intracellular iron homeostasis.

**Hepcidin regulates FPN1 expression of primary erythroblasts**

The regulation of FPN1 was further investigated in fetal liver erythroblasts, which can be induced to differentiate by changing the medium from proliferation medium to differentiation medium. After induction for 48 hours in differentiation medium, expression of the stem cell factor receptor c-kit decreased while the expression of erythroid marker Ter119 and TfR1 increased (Figure 4A).
The hemoglobin mRNA levels significantly increased over a three day induction period, and the TfR1 mRNA levels initially increased and reached a peak at around 36-48 hours before decreasing (Figure 4B), while the size of erythroblasts decreased and hemoglobin protein levels increased (Supplemental figure 2), suggesting that erythroblasts were successfully induced to differentiate. During the differentiation process, expression of the FPN1B transcript decreased significantly over time to reach a baseline level of expression at around 48 hours after differentiation (Figure 4C). In contrast, expression of the FPN1A transcript was quite low in the early stages of differentiation, but increased after 60 hours, and the percentage contribution of FPN1B to total FPN1 mRNA levels decreased from around 80% to around 10% as differentiation progressed. The pattern of FPN1B and FPN1A expression in the differentiation of primary erythroblasts was consistent with the pattern that we previously observed in the differentiation of the erythroblast cell line, G1E cells.18 Meanwhile, FPN1 protein levels decreased during differentiation, paralleling decreased expression levels of the FPN1B transcript (Figure 4D), and supporting that FPN1B is the major transcript that encodes FPN1 protein in developing erythroblasts. TfR1 protein expression peaked at 48 to 60 hours, and then decreased during the differentiation process, consistent with the results shown in Figure 4B and the known role of TfR1 in iron uptake during differentiation of erythroblasts.

In the primary erythroblasts cultured in proliferation medium, endogenous FPN1 protein levels decreased upon treatment with 1 µg/ml of hepcidin for 24 hours (Figure 5A), and the TfR1 levels decreased simultaneously, while ferritin levels increased, suggesting that hepcidin treatment increased intracellular iron availability by blocking iron export through FPN1. The effect of hepcidin on FPN1 expression was studied at different time points during growth in proliferation
medium. FPN1 protein expression decreased slightly after 6 hours of incubation with hepcidin, and it gradually decreased further before reaching a stable baseline after 36 hours. TfR1 expression decreased in parallel (Figure 5B). To confirm the consequences of hepcidin treatment on the intracellular iron concentration of erythroblasts, we measured the activity of IRPs with RNA mobility shift assays. When iron concentrations decreased in samples treated with the iron chelator DFO, IRP2 activity significantly increased, and IRP1 activity increased slightly (Figure 5C); however, treatment with hepcidin markedly reduced IRP2 activity on the gel-shift assay. The protein levels of IRPs were checked with western blots as well, and IRP2 protein levels were increased by DFO treatment and decreased by hepcidin treatment (Figure 5D), while IRP1 protein levels did not change in response to iron or hepcidin treatments. The IRP2 activity and protein levels decreased in response to hepcidin treatment, suggesting that hepcidin treatment increases intracellular iron availability. In addition, the intracellular iron availability of erythroblasts treated by hepcidin was measured by an iron\(^{55}\) retention experiment (Figure 5E). Treatment with 1 µg/ml hepcidin for 24 and 48 hours significantly increased intracellular \(^{55}\)Fe contents, confirming that a hepcidin-mediated decrease in FPN1 expression led to increased intracellular iron concentrations (Figure 5E). Consistent with the FPN1 levels in Figure 2F and 3C, the intracellular \(^{55}\)Fe activity increased in a hepcidin dose-dependent manner; 100 ng/ml hepcidin significantly increased the intracellular \(^{55}\)Fe concentration, and 2 µg/ml hepcidin increased the \(^{55}\)Fe concentration more than 30% (Figure 5F), suggesting that physiologically relevant levels of hepcidin (50 ng/ml to 2 µg/ml) can block iron export by FPN1 and increase intracellular iron concentrations of erythroblasts.\(^{22}\)

**Hepcidin regulates FPN1 expression of erythroblasts in vivo**
To study the effect of hepcidin on FPN1 expression in erythroblasts \textit{in vivo}, we attempted to decrease endogenous levels of hepcidin by maintaining the mice on a low-iron diet. Because hepcidin is mainly regulated at transcriptional level, the hepcidin mRNA levels in liver were measured with qRT-PCR. The hepcidin mRNA levels in liver tissues from mice maintained on the low-iron diet were decreased to barely detectable levels compared to mice on control diet (Figure 6A). The L-ferritin levels in Ter119-positive erythroblasts of bone marrow (Figure 6B) and in spleen (Figure 6C) were significantly lower in mice on the low-iron diet, and TfR1 expression in spleen of mice on the low-iron diet increased (Figure 6C), confirming that iron-diet treatments were successful in inducing systemic iron-deficiency. FPN1 protein levels significantly increased in erythroblasts of mice on the low-iron diet compared to mice on the control diet (Figure 6B) and the increased FPN1 expression in erythroblasts was consistent with the low hepcidin levels, suggesting that hepcidin induced degradation of FPN1 in erythroblasts \textit{in vivo}. FPN1 protein expression was also increased in the spleens of mice maintained on the low-iron diet (Figure 6C).

In primary erythroblasts, we also checked the effect of manipulating iron status on FPN1 protein levels (Figure 6D), but we did not find significant iron-dependent changes, suggesting that FPN1 expression is not regulated by intracellular iron status in erythroblasts, whereas TfR1 was still clearly regulated by iron levels.

To exclude the possibility that increased FPN1 expression in erythroblasts of mice on the low-iron diet was caused by factors other than from decreased hepcidin-mediated degradation, we injected exogenous hepcidin into mice to check the \textit{in vivo} effects of hepcidin on FPN1 expression in erythroblasts. Hepcidin injection significantly decreased FPN1 expression in erythroblasts (Figure 7A). Hepcidin treatment significantly decreased FPN1 expression in the spleen as well
(Figure 7B), while L-ferritin expression increased with hepcidin treatment, suggesting that hepcidin increased intracellular iron availability \textit{in vivo} (although TfR1 expression did not significantly change upon hepcidin treatment in both spleen and erythroblasts). There was little effect of hepcidin injection on FPN1 protein levels in either spleen or erythroblasts when hepcidin was injected into mice maintained on a control diet (Supplemental figure 3), presumably because endogenous hepcidin levels were already high in those mice (Figure 6A).

\textbf{Discussion}

Subcellular localization on the plasma membrane is essential for the iron export function of FPN1, and some mutations of FPN1 that lead to sequestration within intracellular vesicles cause a specific type of hemochromatosis.\textsuperscript{23,24} The endogenous FPN1 in primary human erythroblasts derived from CD34+ cells was previously reported to be localized in cytosol,\textsuperscript{19} raising the possibility that FPN1 in erythroblasts might not have the capacity to export iron and to be regulated by hepcidin. Here, our results with both transiently transfected FPN1 in erythroblast cell lines and endogenous FPN1 in primary fetal liver erythroblasts demonstrated that FPN1 trafficks to the plasma membrane, the subcellular location required for FPN1 to export iron and to be regulated by hepcidin. Furthermore, our results in both erythroblast cell lines and primary erythroblasts showed that hepcidin treatment within a physiological concentration range (50 to 2000 ng/ml) decreased FPN1 expression (Figures 2, 3, 5) and increased intracellular iron availability, consistent with the finding that FPN1 localizes on the plasma membrane of erythroblasts.\textsuperscript{22}

There are two FPN1 transcripts, including FPN1A, which is ubiquitously expressed and is
subject to translational repression by the IRP/IRE machinery, and FPN1B, which is specifically expressed in enterocytes and erythroblasts and is not regulated by IRPs. Consistent with our previous results in the erythroblast cell line, G1E cells, FPN1B is the major transcript in cultured primary erythroblasts (Figure 2), and its levels decreased during the differentiation of erythroblasts, whereas expression of the FPN1A transcript increased during differentiation. Levels of FPN1 protein decreased and correlated with FPN1B transcript levels during differentiation, confirming that FPN1 protein is mainly generated from FPN1B in developing erythroblasts. In cell types such as macrophages and hepatocytes, FPN1 protein levels are positively regulated by intracellular iron concentrations. In contrast, FPN1 protein expression remains constant in erythroblasts after incubation with FeNTA or DFO for 18 hours, consistent with the observations that FPN1B (the FPN1 transcript without a 5'-IRE) is the major FPN1 transcript in erythroblasts, and suggesting that expression of FPN1 protein in developing erythroblasts is regulated mainly at the systemic level by hepcidin.

Since erythropoiesis is the major iron-consuming process in vertebrates, it is not surprising that expression of hepcidin is regulated by erythropoiesis, and erythropoietic signals can override some other hepcidin regulatory signals such as iron overload or inflammation. Erythropoiesis induced by phlebotomy or hypoxia has been shown to repress hepcidin expression, which allows more iron to flow into the circulating transferrin pool to support red blood cell production. Moreover, erythropoiesis can inhibit both inflammatory and iron-sensing pathways, probably via the suppression of the STAT3 and SMAD4 pathways in vivo, to repress hepcidin transcription. In beta-thalassemia, anemia caused by reduced expression of beta-globin chains results in suppression of hepcidin synthesis in spite of severe iron overload. The exact mechanism by
which erythropoiesis regulates hepcidin expression is not known yet, but in beta-thalassemia it might be through GDF15 and TWSG1, two molecules of the TGF-β superfamily, which are remarkably upregulated in erythroblasts of beta-thalassemia patients. In any case, the mechanism by which erythropoiesis regulates hepcidin expression remains to be fully elucidated.

Here, we have shown that hepcidin regulates FPN1 expression and intracellular iron homeostasis of erythroblasts, raising the possibility that hepcidin may be directly involved in regulation of erythropoiesis. The involvement of FPN1 and hepcidin in regulation of erythropoiesis was observed in several previous studies. In polycythaemia (Pcm) mice, a 58bp microdeletion in the FPN1A promoter alters the canonical transcriptional start sites and eliminates the IRE in the 5'UTR of the FPN1A transcript, resulting in increased FPN1 protein expression in some tissues and leading to polycythemia in heterozygous mice and microcytic anemia in young homozygous mice. Both the polycythemia of heterozygous mice and the microcytic anemia of homozygous mice improved spontaneously in adults, and the improvement correlated with increased hepcidin expression, which supports the possible role of hepcidin-FPN1 interactions in regulation of erythropoiesis. In another study, hepcidin treatment reduced erythroid colony formation when cultures were performed in medium that contained low erythropoietin concentrations, providing direct evidence for hepcidin involvement in erythropoiesis. Anemia of chronic diseases (ACD) is a common form of anemia associated with chronic inflammatory disorders that is characterized by high hepcidin expression. Hepcidin is strikingly high in ACD patients, probably because inflammatory factors including IL-6 levels increase hepcidin transcription. Hepcidin subsequently blocks iron absorption in the duodenum and iron recycling in reticuloendothelial macrophages, leading to systemic iron deficiency. In contrast to iron deficiency
anemia (IDA) in which patients have low iron saturations (<10%) and low ferritins (<30 ng/ml) in serum, ACD patients have low iron saturations (<15%) but high serum ferritins (>200ng/ml, perhaps because macrophages, the main source of serum ferritin, are iron overloaded 33). It has been a mystery that the mean corpuscular volume of ACD patients is mostly normal compared to patients suffering IDA. Considering that both ACD and IDA patients have limited iron and one of the biggest distinctions between ACD and IDA is the higher hepcidin levels in ACD, the nearly normal mean corpuscular volume of ACD patients suggests that the interaction of hepcidin with FPN1 in erythroblasts may increase erythroid iron stores at an important developmental stage.34

The discovery of FPN1B expression and hepcidin binding in erythroblasts may have important physiological implications. Because FPN1 is blocked by hepcidin, FPN1 in erythroblasts is active only in iron-deficient conditions when hepcidin is low. FPN1B expression in erythroblasts probably represents a fine-tuning mechanism to prevent misallocation of iron. In iron-replete conditions, down-regulation of FPN1 ensures that erythroblasts retain iron to produce hemoglobin, helping to prevent complete saturation of circulating transferrin. Conversely, in iron-deficient conditions, erythroblasts allow other tissues to take priority by exporting their iron, similar to a process that likely occurs in duodenal enterocytes, and thereby helping other tissues avoid severe iron depletion. Considering that erythroblasts have efficient iron uptake machinery (TfR1 is highly expressed on erythroblasts and more than 80% of total TfR1 in vivo is expressed on erythroblasts) and only about 1% of red blood cells in human need to be replaced daily, it is probably better for the organism to decrease erythropoietic activity during a period of iron deficiency than to risk developing iron deficiency in vital organs such as the brain and heart. The connection between hepcidin and ferroportin expression on erythroblasts likely explains why
anemia is usually the first prominent symptom of iron deficiency. Though hepcidin levels are extremely low in hemochromatosis, the blood cell indices are normal in mouse models of hemochromatosis, and the MCV in hemochromatosis patients is slightly higher than in control groups, most likely because high transferrin saturations can support high iron influx into erythroblasts, enabling them to override the export capacity of FPN1.35,36

In conclusion, the results of our study show that the iron regulatory hormone hepcidin can regulate FPN1 expression of the erythroid precursors at a point in development when FPN1 expression is not yet regulated by the IRE/IRP system. FPN1 expression in erythroblasts may represent a fine-tuning mechanism that maintains systemic iron homeostasis and ensures that erythroblasts titrate the amount of iron they retain according to organismal iron status. We predict that mice with a conditional deletion of FPN1 in erythroblasts will not be able to maintain systemic iron homeostasis; in iron-deficient conditions, the animals may maintain normal hematocrits or develop polycythemia, even while they are experiencing iron starvation in non-erythropoietic tissues. Thus, it may be possible to address the physiological significance of FPN1 and hepcidin binding in erythropoiesis with the FPN1 conditional knockout mice.

Acknowledgements

We thank Dr. Ivana De Domenico for providing us with the pEGFP-N1-FPN1 plasmid and Dr. Jeff Miller for constructive comments on the paper. This work was supported by the intramural program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.
Authorship:

Contribution: D.L.Z. designed and performed experiments, analyzed data, and wrote the paper; T.S., H.O.W. and T.T. performed experiments; M.C.G. performed experiments and analyzed data; and T.A.R. oversaw the study, analyzed data, and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

References:


derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010;116(9):1574-1584


Figure legend:

Figure 1. FPN1 is localized to the plasma membrane of K562 erythroblast cells and primary erythroblasts. A. K562 cells were transiently transfected with plasmids to express FPN1GFP and the plasma membrane marker pDsRed-Monomer F for 24 hours to examine their colocalization. B. Endogenous FPN1 localized mainly to the plasma membrane of primary erythroblasts. Fetal liver erythroblasts were incubated with rabbit anti-FPN1 and mouse anti-TfR1 antibodies, and were then labeled with FITC-donkey-anti-rabbit and CY3-donkey-anti-mouse antibodies. Pictures were taken with the Leica SP5 confocal microscope. C. Immunoprecipitations of cell surface proteins demonstrated that FPN1 localizes on the plasma membrane. Fetal liver erythroblasts were incubated with or without hepcidin for 24 hours, then the cell-surface protein were labeled with or without Sulfo-NHS-LC-Biotin. The cell lysates were incubated with Streptavidin Gel and the immunoprecipitated proteins were immunoblotted with anti-FPN1 and anti-TfR1 antibodies.
Figure 2. FPN1 expression is regulated by hepcidin in transfected erythroblast cell lines in a
dose and time-dependent manner as indicated by FACS analysis. A. Validation of the use of
FACS analysis to measure iron-dependent TfR1 expression. K562 cells were treated with 100 µM
FeNTA or 100 µM DFO for 18 hours, and cells were then labeled by APC-labeled TfR1 antibodies
and checked by FACS analysis. B. Expression of FPN1 increases TfR1 expression in K562 cells.
K562 cells were transiently transfected with pEGFP-N1-FPN1 to express the fusion protein
FPN1GFP for 24 hours, and the expression of TfR1 was then measured by FACS. Expression of
FPN1 in K562 (C) and MEL (D) cells was downregulated by hepcidin. Cells were transiently
transfected with pEGFP-N1 or pEGFP-N1-FPN1 and incubated with 1 µg/ml of hepcidin for 24
hours and the GFP-positive cells were then measured by FACS. E. Time-dependent regulation of
FPN1 by hepcidin. K562 cells were transfected with pEGFP-N1-FPN1 or pEGFP-N1 vectors for
12 hours, and then incubated with or without 1 µg/ml of hepcidin. The GFP positive cells were
measured by FACS at the indicated time points. F. Dose-dependent regulation of FPN1 by
hepcidin. K562 cells transfected with pEGFP-N1-FPN1 or pEGFP-N1 vectors were incubated
with hepcidin of indicated concentrations for 24 hours. The GFP positive cells were measured by
FACS. G. Hepcidin treatment reverses the FPN1-induced increase of TfR1 in K562 cells. K562
cells were transiently transfected with pIRES2EGFP-FPN1, and incubated with or without 1
µg/ml of hepcidin for 24 hours. The expression levels of TfR1 were measured by FACS analysis
in GFP-positive cells. All of the experiments (A-G) were independently repeated at least twice
with triplicate samples assessed at each time point. a.u. arbitrary unit, **, p<0.01, ***, p<0.001
Figure 3. FPN1 protein expression levels in transfected erythroblast cell lines are directly regulated by hepcidin in a dose and time-dependent manner A. Hepcidin regulates FPN1 expression and intracellular iron status of K562 cells. K562 cells transiently transfected with pEGFP-N1 or pEGFP-N1-FPN1 plasmids to generated cells that expressed GFP alone, or the FPNGFP fusion proteins, and were incubated with or without 1 µg/ml of hepcidin for 24 hours. B. Time-dependent regulation of FPN1 by hepcidin in K562 cells. K562 cells were transfected with pEGFP-N1-FPN1 for 12 hours, then incubated with 1 µg/ml of hepcidin at the indicated time points. C. Dose-dependent regulation of FPN1 by hepcidin. K562 cells were transfected with pEGFP-N1-FPN1 and incubated with hepcidin at the indicated concentrations for 24 hours. Total cell lysates were separated with 4-20% Tris-glycine gels and then were transferred to nitrocellulose membranes. The membranes were then incubated with antibodies for GFP, FPN1, TfR1, IRP2, IRP1 and alpha-tubulin, respectively. All of the experiments were repeated at least twice.

Figure 4. Distinctive expression patterns of the two FPN1 transcripts during differentiation of fetal liver erythroblasts. A. Expression of c-Kit, TER119 and TfR1 in the process of differentiation of erythroblasts. After being cultured in either proliferation or differentiation medium for 48 hours, erythroblasts were incubated with PE-labeled anti-c-Kit, PE CY7-labeled anti-TER119, or FITC-labeled anti-TfR1 antibodies (BD Pharmingen), followed by FACS analysis. B. mRNA expression of hemoglobin adult alpha-chain (HBA) and TfR1 during the differentiation of erythroblasts. C. mRNA expression of FPN1A, FPN1B and FPN1 during the differentiation of erythroblasts. D. Protein expression of FPN1, TfR1 and alpha-tubulin during the differentiation of
erythroblasts. At different time points after being cultured in differentiation medium, erythroblasts were harvested and total RNA or protein were prepared for qRT-PCR (B, C) or western blot (D) analysis. The qRT-PCR results were normalized with actin mRNA. The qRT-PCR experiments were repeated three times with triplicate samples each time, the western blots were repeated at least twice. (a.u. signifies arbitrary units.)

Figure 5. Hepcidin regulates endogenous FPN1 expression and intracellular iron levels of fetal liver erythroblasts. A. Expression of endogenous FPN1 in erythroblasts was decreased after a 24 hour hepcidin treatment. Erythroblasts in proliferation medium were incubated with 1 µg/ml hepcidin for 24 hours, and protein expression was then measured by western blot analysis for FPN1 and TfR1 in membrane fractions of sample lysates, and for L-ferritin in soluble fractions of sample lysates. Ponceau S staining of a specific portion of the gel was used as a loading control. B. Expression of FPN1 at different time points of incubation with hepcidin during growth in proliferation medium. C. IRP2 activity was decreased by hepcidin in erythroblasts. Erythroblasts were incubated with 1 µg/ml hepcidin for 24 or 48 hours, or with 100 µM FeNTA or DFO for 18 hours, and samples were then prepared with or without beta-mercaptoethanol to measure IRP activity by electrophoresis mobility shift assay (EMSA). The density of the bands was analyzed with Image J (http://imagej.nih.gov/ij/) and normalized to IRP1 activity after beta-mercaptoethanol treatment and statistical comparisons were performed. D. Western blot analyses showed decreased IRP2 protein levels in samples treated by hepcidin. The cells were treated as described in C. E. Hepcidin increases intracellular iron contents of erythroblasts. Erythroblasts in one well of a 6-well plate in proliferation medium were loaded with $^{55}$Fe by
incubation with 5 µCi $^{55}$Fe (0.2 µg) for 2 hours, and were then washed twice and incubated with 1 µg/ml of hepcidin for 24 or 48 hours, following which intracellular $^{55}$Fe levels were measured with a Liquid Scintillation Counter. F. Hepcidin increases intracellular iron levels in a dose-dependent manner. Erythroblasts in proliferation medium were loaded with $^{55}$Fe as described in E, and were then incubated with hepcidin of indicated concentrations for 24 hours, following which intracellular $^{55}$Fe levels were measured with Liquid Scintillation Counter. a.u. arbitrary unit. Experiments in A-D were repeated three or more times, and experiments in E and F were repeated twice with triplicate samples for each time point. *, p<0.05, **, p<0.01, ***, p<0.001.

Figure 6. Expression of FPN1 in erythroblasts of mouse bone marrow increased in mice maintained on a low-iron diet. A. Expression of hepcidin mRNA was decreased to barely detectable levels in the livers of mice on low-iron diet. Total RNA was prepared and hepcidin expression was measured by qRT-PCR and normalized to actin mRNA levels. a.u. arbitrary unit. B. FPN1 expression increased in Ter119-positive erythroblasts from the bone marrow of mice maintained on a low-iron diet compared to mice on control diet. Expression of FPN1 and L-ferritin was measured by western blot analyses in total cell lysates. A distinctive band in Ponceau S staining was used as a loading control. C. FPN1 expression increased in the spleens of mice maintained on the low-iron diet. Expression levels of FPN1, Tfr1, L-ferritin and alpha-tubulin were measured by western blot analyses. D. FPN1 expression, unlike Tfr1, is not regulated by iron status in cultured primary erythroblasts. Fetal liver erythroblasts were cultured in proliferation medium and incubated with 100 µM of FeNTA or DFO for 18 hours. Then the membrane fractions were prepared and the expression levels of FPN1, Tfr1 and alpha-tubulin was
measured by western blots. The experiments A-C were repeated in three animals in each group, and D was repeated twice.

**Figure 7. Expression levels of FPN1 in erythroblasts of mouse bone marrow and in mouse spleen were decreased by hepcidin injection.** A. Expression levels of FPN1 and TfR1 in Ter119-positive erythroblasts or the Ter119-negative cells from bone marrow were compared by western blot analyses after injection of either hepcidin or PBS for 24 hours. A band from Ponceau S staining of the gel was used as a loading control. B. Hepcidin injections decreased FPN1 expression in mouse spleen. Expression levels of FPN1, TfR1, L-ferritin and alpha-tubulin were measured by western blots. The experiments were performed in mice maintained on a low-iron diets as described in the Materials and Methods. Experiments A and B were repeated in three animals in each group.
Figure 1

A  
FPN1GFP  DsRed Monomer F  Merge

B  
FPN1  TfR1  Merge

C  
IP: Streptavidin

<table>
<thead>
<tr>
<th></th>
<th>Biotin</th>
<th>Hepcidin</th>
<th>FPN1</th>
<th>Tfr1</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>+</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>-</td>
<td>+</td>
<td>65kDa</td>
<td>98kDa</td>
</tr>
</tbody>
</table>

65kDa

98kDa
Figure 3

A

<table>
<thead>
<tr>
<th>Hepcidin</th>
<th>GFP</th>
<th>+</th>
<th></th>
<th>FPN1GFP</th>
<th>+</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-GFP</td>
<td></td>
<td></td>
<td>90kDa</td>
<td></td>
<td></td>
<td>30kDa</td>
</tr>
<tr>
<td>FPN1</td>
<td></td>
<td></td>
<td>90kDa</td>
<td></td>
<td></td>
<td>98kDa</td>
</tr>
<tr>
<td>Tfr1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100kDa</td>
</tr>
<tr>
<td>IRP2</td>
<td></td>
<td></td>
<td>100kDa</td>
<td></td>
<td></td>
<td>100kDa</td>
</tr>
<tr>
<td>IRP1</td>
<td></td>
<td></td>
<td>50kDa</td>
<td></td>
<td></td>
<td>50kDa</td>
</tr>
<tr>
<td>Tubulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50kDa</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>Time</th>
<th>2h</th>
<th>4h</th>
<th>6h</th>
<th>12h</th>
<th>24h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepcidin</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>α-GFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FPN1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tfr1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRP2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRP1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th>Hepcidin</th>
<th>0</th>
<th>50</th>
<th>100</th>
<th>200</th>
<th>500</th>
<th>1000</th>
<th>2000</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-GFP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FPN1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tfr1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRP2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRP1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 4

A

B

C

D

Differentiation 0h 6h 12h 24h 36h 48h 60h 72h

FPN1
TIR1
Tubulin

65kDa
98kDa
50kDa
Figure 5

A

Membrane fraction
- - + +

Hepcidin
FPN1 65kDa
TfR1 90kDa
Ponceau staining

Soluble fraction
22kDa
Ferritin
Ponceau staining

B

Hepcidin 0h 6h 12h 24h 36h 48h
FPN1 65kDa
TfR1 90kDa
Tubulin 50kDa

C

IRP1 band density analysis
IRP2 band density analysis

D

FeNTA Cont DFO Cont 24h Cont 48h Hep Cont 24h Cont 48h Hep Cont 48h Hep
IRP1
IRP2
Tubulin

E

Intracellular iron levels in FLC cells
- Control
- Hepcidin

F

Intracellular iron levels in FLC cells
- 24 hours
- 48 hours

Hepcidin concentration (ng/ml)
Figure 6

A. Liver hepcidin mRNA levels

B. Bone marrow TER119-erythroblasts

C. Spleen protein expression

D. Primary erythroblasts
Figure 7

A

Protein expression of bone marrow cells

<table>
<thead>
<tr>
<th></th>
<th>Ter119 negative cells</th>
<th>Erythroblasts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hep</td>
<td>-  -  +  +</td>
<td>-  -  +  +</td>
</tr>
<tr>
<td>FPN1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tfr1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ponceau Staining</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

Spleen protein expression

<table>
<thead>
<tr>
<th></th>
<th>Hep</th>
</tr>
</thead>
<tbody>
<tr>
<td>FPN1</td>
<td></td>
</tr>
<tr>
<td>Tfr1</td>
<td></td>
</tr>
<tr>
<td>FtL</td>
<td></td>
</tr>
<tr>
<td>Tubulin</td>
<td></td>
</tr>
</tbody>
</table>
Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts

De-Liang Zhang, Thomas Senecal, Manik C. Ghosh, Hayden Ollivierre-Wilson, Tiffany Tu and Tracey A. Rouault